European asset manager Candriam has launched the Candriam Equities L Oncology Impact fund, which will invest in listed companies focused on the diagnosis, profiling and treatment of cancer.
Cancer is the second-leading cause of death globally and 40% of all men and women will be diagnosed with cancer at some point during their lifetimes.
Ageing global populations are projected to increase worldwide cancer deaths by 60% from to 13 million from eight million by 2030.
The new Candriam fund supports the development of a wide range of cancer diagnostics and treatments and seeks to identify companies behind breakthrough innovations that could change the way we treat cancer. In addition, 10% of the fund’s management fees will support cancer research through institutes.
A number of technological advances– including immunotherapy, targeted therapy, liquid biopsies, tumour sequencing, nanotechnology, robotic surgery, artificial intelligence and Big Data – provide a ray of hope for cancer patients and their families.
Innovation in cancer treatments is impacting sectors such as biotech, pharmaceuticals, artificial intelligence and research and involves companies from all over the world.
Rudi Van den Eynde, head of thematic equity, said: “We see a lot of innovation in the treatment of many diseases and particularly cancer and want to identify those companies with strong growth potential.
Vincent Hamelink, chief investment officer – investment management, added: “The fund is designed to generate a profit for investors while at the same time benefiting cancer research and having an impact on society.”
The Candriam Equities L Oncology Impact is a sub-fund of Candriam Equities L, a Sicav (Société d’investissement à capital variable) domiciled in Luxembourg and it is managed by Candriam Luxembourg.
Candriam Equities L Oncology Impact is currently registered for marketing in Luxembourg, Austria, Switzerland, Germany, Spain, France, the United Kingdom, Italy, the Netherlands and Portugal.